Importantly, the application of IGF2BP1 inhibitors have demonstrated promising anti-cancer efficacy in patient-derived xenograft (PDX) mouse models, and provide a novel targeted therapeutic strategies for CCA [76]. The gene discussed is IGF2BP1; the disease is cholangiocarcinoma.